The Cleanroom Construction Market: Capitalizing on Pharmaceutical Manufacturing’s Essential Infrastructure

Every biologic, sterile injectable and cell therapy is made inside a cleanroom: a room engineered to control particles, microbes, temperature, humidity and pressure. As biologics and advanced therapies scale, so does demand for the specialists who design, build and qualify these spaces.

For investors looking at pharma services, cleanroom construction is an attractive way to back the industry’s growth without taking drug-development risk. Spending is driven by regulation and capacity, barriers to entry are real, and the best operators turn one-off projects into years of recurring service revenue. This guide covers what you need to know to evaluate the sector: the technical basics, the business models, project economics, the competitive landscape and what drives valuation.

The Market at a Glance

The global cleanroom technology and construction market reached an estimated $10.04 billion in 2025 and is forecast to reach $14.16 billion by 2030 (Mordor Intelligence). North America’s cleanroom construction market alone was valued at about $1.2 billion in 2023 and is expected to grow at over 7% a year through 2032 (GMI). Asia-Pacific is the fastest-growing region, at roughly 7.6% a year.

Cleanroom Basics: What Drives Cost

Two frameworks define how clean a room must be. ISO 14644-1 sets nine classes based on airborne particle counts, with ISO 1 the cleanest. Since 2001 it has replaced the old US “Class 100 / 10,000 / 100,000” system, though you’ll still hear those terms. For sterile medicines, EU GMP Annex 1 adds Grades A to D, which map onto ISO classes. The updated Annex 1 took effect in August 2023 and has raised expectations for contamination control strategies, monitoring and barrier technology, driving a wave of upgrades.

EU GMP grade	ISO class (at rest / in operation)	Typical use
Grade A	ISO 5 / ISO 5	Aseptic filling and open sterile operations, usually inside isolators or unidirectional-airflow zones
Grade B	ISO 5 / ISO 7	Background room for Grade A work
Grade C	ISO 7 / ISO 8	Solution preparation, filling of terminally sterilised products
Grade D	ISO 8 / not defined	Component handling and lower-risk steps

Why this matters to an investor: cost scales with cleanliness. An ISO 5 suite needs far more filtered air, tighter controls and more qualification work than an ISO 8 room, and the most extreme classes (ISO 1–3, used mainly in semiconductors) can cost up to 20 times more per square foot than ISO 8. Most pharmaceutical projects target ISO 5–7, which balances contamination control against cost.

A cleanroom project is really four systems working together:

Four Business Models

Cleanroom firms range from specialist designers to full turnkey contractors. Where a firm sits determines how much of each project it captures, its margins and the risks it carries.

Model	What they do	Revenue per project	Gross margin	Main risk
Design-only	Engineering design, specifications, airflow modelling, construction oversight	About 5–15% of construction cost	50–70%	Professional liability; limited control of outcomes; hard to scale talent
Design-build	Design and construction under a single contract	$2–20M+	20–40%	Fixed-price cost overruns, schedule penalties, bonding limits
Turnkey	Everything from planning to equipment, qualification and start-up	$10–100M+	Varies with scope	Requires deep process, validation and regulatory capabilities
Modular manufacturer	Prefabricated cleanroom systems built in a factory	Varies; often smaller projects	Varies with price competition	Factory capital up front; price pressure in competitive bids

Two trends stand out. Design-build has gained share because owners want one accountable party and faster schedules. Modular is the fastest-growing segment: modular suites can be installed up to 50% faster than traditional “stick-built” rooms and can be expanded or relocated later, which suits companies with uncertain capacity needs.

What’s Driving Demand

Biologics and Cell and Gene Therapy

Biologics such as monoclonal antibodies, proteins and vaccines are made in cell-culture processes that need tightly controlled ISO 5–7 space. Cell and gene therapies add a multiplier: many are made patient by patient, which favours many smaller, distributed facilities rather than a few large plants, so there are more projects for the same output.

Regulation

Pharmaceutical cleanrooms are mandatory, not optional. The revised EU GMP Annex 1, ongoing FDA inspection findings, and GMP standards in China, India and Brazil moving closer to US and EU norms all push manufacturers to upgrade existing facilities and build new ones to current expectations.

Automation and Digital Monitoring

Robotics, continuous manufacturing and real-time environmental monitoring all need purpose-built cleanroom infrastructure. Energy efficiency is also a growing priority: cleanrooms run their HVAC around the clock, so variable-speed drives, low-pressure-drop components and predictive maintenance are increasingly standard.

Geography

Asia-Pacific is growing fastest as China, India, South Korea and Southeast Asia build GMP capacity. In the US and Europe, efforts to bring drug and semiconductor manufacturing closer to home are adding further demand.

Project Economics

Project tier	Typical value	Typical scope	Timeline
Small modular	$0.5–2M	Lab, pilot or clinical suites, usually ISO 7–8	3–6 months
Mid-scale	$2–10M	Manufacturing suites in existing buildings, CDMO expansions, cell therapy or viral vector space, ISO 5–7	9–18 months
Large facility	$10–50M+	Full manufacturing facilities with multiple grades, utilities and process integration	24–36 months
Campus	$50–500M+	Multi-building manufacturing campuses	3–5+ years

As a rough benchmark, basic ISO 7–8 space costs about $200–500 per square foot, while sophisticated ISO 5 suites with integrated equipment can reach $1,000–3,000 or more, compared with $100–200 for conventional commercial space. Contractor gross margins typically fall between 20% and 40%. Fixed-price design-build work can sit at the top of that range when projects are well executed, but carries the downside if they aren’t.

The Real Opportunity: The Cleanroom as a Gateway

The most interesting part of this market is not the build itself. The firm that designs and builds a client’s cleanroom knows that facility better than anyone, and has worked closely with the client’s engineering, quality and leadership teams for months or years. That makes it the natural provider of everything the room needs for the rest of its life.

“The firm that builds a client’s cleanroom becomes the natural provider of everything that room needs for the rest of its life.”

Lifecycle service	What it involves	Why it matters
Qualification (IQ / OQ / PQ)	Documenting that systems are installed correctly, operate within limits and perform in production	Often 10–20% of construction value combined, and required before commercial manufacturing
Environmental monitoring	Routine particle and microbial monitoring, pressure and temperature trending, monitoring-system support	Ongoing, and among the fastest-growing segments
Calibration	Particle counters, sensors, gauges and airflow instruments	Recurring annual revenue
Temperature mapping	Studies for storage areas, cold rooms and stability chambers	Typically $10,000–50,000+, repeated every 2–3 years
Maintenance and requalification	Filter replacement, HVAC service, repairs, modifications and expansions	Recurring revenue plus follow-on projects

Professional services already make up about two-thirds of the cleanroom technology market (Towards Healthcare), with validation, qualification and certification expected to grow fastest. Firms that pair construction with these services see better retention and higher lifetime value per client, and the market tends to reward that with higher valuations.

Build, Buy or Partner?

For an existing pharma services company, such as a calibration, validation or quality firm, adding cleanroom capability is a logical next step, but building it from scratch is hard. Specialist engineers are scarce, and credibility, subcontractor networks and bonding capacity take years to establish. Acquiring an established contractor delivers capability, clients and backlog immediately, but brings integration and liability risk. For many firms, a strategic partnership is the best first step: it allows cross-referrals and bundled offers now, and can become an acquisition once the fit is proven.

Competitive Landscape and Consolidation

The market combines a handful of global engineering and construction firms, such as Exyte (formerly M+W Group), specialist modular suppliers and a long tail of regional design-build contractors. Large players bring global reach, in-house capabilities and bonding capacity. Regional specialists compete on relationships, responsiveness and niche expertise, such as cell therapy or viral vector suites, and often earn strong margins in their home markets, but they hit limits on project size and geography.

Consolidation is under way. The acquisition of Ardmac by Purever Industries in July 2024 is one example. Large pharma companies and CDMOs prefer fewer, more capable vendors, and private equity sees a fragmented market that suits a buy-and-build strategy. For investors, that means two things: well-run regional firms are attractive targets, and rolling them up only works if key engineers and client relationships stay through integration.

Risks to Underwrite

• Execution. A room that fails to reach its classification, or a delayed qualification, can turn a profitable fixed-price job into a loss, especially where contracts carry penalties for late delivery.
• Regulatory change. Annex 1, FDA expectations and ISO 14644 updates keep moving. Firms that fall behind deliver facilities that fail inspection or need costly remediation.
• Talent. Experienced cleanroom engineers and HVAC specialists are scarce, and talent, not demand, is often what limits growth.
• Cyclicality. Pharma is relatively defensive, but biotech funding cycles and post-merger site rationalisation can delay projects. Diversified clients and exposure to other sectors (semiconductors, medical devices) reduce the risk.

Valuation: What Earns a Premium

Public comparables are limited, so valuations are usually benchmarked against neighbouring sectors. General construction and engineering firms often trade at around 6–12x EBITDA. Specialist pharma service providers (CROs, CDMOs and testing labs) often command 12–20x, reflecting higher margins and recurring revenue. Cleanroom contractors sit between the two, and where they land depends on three things: how much revenue recurs, the depth of their pharma track record and exposure to the fastest-growing segments. Private deal multiples are rarely disclosed, but well-positioned firms have reportedly traded in the low-to-mid teens.

What This Means for Investors

Cleanroom construction offers mandatory, regulation-driven demand, high barriers to entry, and a clear path from project revenue to recurring services. When evaluating a target, we’d focus on these questions:

• What share of revenue comes from recurring qualification, monitoring and maintenance work rather than one-off builds?
• How deep is the pharma track record: reference projects, inspection history and repeat clients?
• How are contracts structured, and how have fixed-price projects performed historically?
• Is there enough working capital and bonding capacity to support the growth plan?
• How concentrated are revenues by client, region and end market?
• Will key engineers and client relationships stay after the deal?

Terraforme Biosciences supports investors with technical and commercial due diligence on life sciences service businesses. Learn more about our M&A support.